Synergistic Effect of the Combined Action of Targeted and Photodynamic Therapy on HER2-Positive Breast Cancer

Overview

Journal Dokl Biochem Biophys

Specialties Biochemistry
Biophysics

Date 2023 Feb 14

PMID 36786996

Authors

I V Balalaeva

L V Krylova

M A Karpova

A A Shulga

E V Konovalova

E L Guryev

S M Deyev

Affiliations

Soon will be listed here.

Abstract

Development of combined schemes for the treatment of oncological diseases is a promising strategy to improve the effectiveness of antitumor therapy. This paper shows the fundamental possibility of multiplying the antitumor effect by combining targeted and photodynamic therapy. It was demonstrated that sequential treatment of HER-2 positive breast cancer cells with the targeted toxin DARPin-LoPE and the photoactive compound photodithazine leads to a synergistic enhancement of their effect. In the future, this approach is intended to achieve the maximum therapeutic effect while minimizing the risks of negative side effects.

References

Gerber D . Targeted therapies: a new generation of cancer treatments. Am Fam Physician. 2008; 77(3):311-9. View

Vijaya Padma V . An overview of targeted cancer therapy. Biomedicine (Taipei). 2015; 5(4):19. PMC: 4662664. DOI: 10.7603/s40681-015-0019-4. View

Higgins M, Baselga J . Targeted therapies for breast cancer. J Clin Invest. 2011; 121(10):3797-803. PMC: 3195649. DOI: 10.1172/JCI57152. View

Shapira A, Benhar I . Toxin-based therapeutic approaches. Toxins (Basel). 2011; 2(11):2519-83. PMC: 3153180. DOI: 10.3390/toxins2112519. View

Sabnis A, Bivona T . Principles of Resistance to Targeted Cancer Therapy: Lessons from Basic and Translational Cancer Biology. Trends Mol Med. 2019; 25(3):185-197. PMC: 6401263. DOI: 10.1016/j.molmed.2018.12.009. View

Plana D, Palmer A, Sorger P . Independent Drug Action in Combination Therapy: Implications for Precision Oncology. Cancer Discov. 2022; 12(3):606-624. PMC: 8904281. DOI: 10.1158/2159-8290.CD-21-0212. View

Boshuizen J, Peeper D . Rational Cancer Treatment Combinations: An Urgent Clinical Need. Mol Cell. 2020; 78(6):1002-1018. DOI: 10.1016/j.molcel.2020.05.031. View

Agostinis P, Berg K, Cengel K, Foster T, Girotti A, Gollnick S . Photodynamic therapy of cancer: an update. CA Cancer J Clin. 2011; 61(4):250-81. PMC: 3209659. DOI: 10.3322/caac.20114. View

Shramova E, Chumakov S, Shipunova V, Ryabova A, Telegin G, Kabashin A . Genetically encoded BRET-activated photodynamic therapy for the treatment of deep-seated tumors. Light Sci Appl. 2022; 11(1):38. PMC: 8861062. DOI: 10.1038/s41377-022-00729-4. View

10.

Mishchenko T, Balalaeva I, Gorokhova A, Vedunova M, Krysko D . Which cell death modality wins the contest for photodynamic therapy of cancer?. Cell Death Dis. 2022; 13(5):455. PMC: 9106666. DOI: 10.1038/s41419-022-04851-4. View

11.

Weldon J, Pastan I . A guide to taming a toxin--recombinant immunotoxins constructed from Pseudomonas exotoxin A for the treatment of cancer. FEBS J. 2011; 278(23):4683-700. PMC: 3179548. DOI: 10.1111/j.1742-4658.2011.08182.x. View

12.

Guryev E, Volodina N, Shilyagina N, Gudkov S, Balalaeva I, Volovetskiy A . Radioactive (Y) upconversion nanoparticles conjugated with recombinant targeted toxin for synergistic nanotheranostics of cancer. Proc Natl Acad Sci U S A. 2018; 115(39):9690-9695. PMC: 6166851. DOI: 10.1073/pnas.1809258115. View

13.

Bhuvaneswari R, Ng Q, Thong P, Soo K . Nimotuzumab increases the anti-tumor effect of photodynamic therapy in an oral tumor model. Oncotarget. 2015; 6(15):13487-505. PMC: 4537029. DOI: 10.18632/oncotarget.3622. View